Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 43Nivolumab 24Gemcitabine 23Cyclophosphamide 22Paclitaxel 17Capecitabine 16fludarabine 15Ipilimumab 14aldesleukin 11Docetaxel 11130-nm albumin-bound paclitaxel 11Trastuzumab 10Cetuximab 10Bevacizumab 10Albumin-Bound Paclitaxel 9fludarabine phosphate 8Specimen Handling 8Interleukin-2 8Fluorouracil 8Cisplatin 8Biopsy 8Radiosurgery 7Oxaliplatin 7Irinotecan 7durvalumab 6avelumab 6Temozolomide 6Pemetrexed 6Leucovorin 6Carboplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasm Metastasis × utomilumab × Clear all
NCT03217747 2026-05-05

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
173 enrolled 28 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡